For research use only
| Cat No. | ABC-TC1175 |
| Product Type | Human Pancreas Cancer Cell Lines |
| Cell Type | Epithelial-like |
| Species | Human |
| Growth Conditions | 37 ℃, 5% CO2 |
| Product Code | Suit-2; SUIT 2; SUIT2; Suit2; SUIzo Tumor-2 |
SUIT-2 human pancreatic cancer line from Japanese male liver metastasis shows epithelial morphology, pancreatic markers,aneuploidy,tumorigenic metastatic.
SUIT-2 cell line is a human pancreatic ductal adenocarcinoma (PDAC) cell line originally derived from a liver metastasis in a Japanese male. This cell line exhibits two distinct subpopulations including spindle-shaped (mesenchymal) and polygonal (epithelial) cells. SUIT-2 cells harbor a complex karyotype with known mutations including KRAS G12D, a common driver in pancreatic cancer, and show p53 loss-of-function. SUIT-2 is highly tumorigenic and metastatic in nude mice, forming primary tumors and lymph node metastases. In addition, these cells express epithelial markers such as E-cadherin and CK19 and shows variable expression of mesenchymal markers depending on the subclone. This cell line is widely used in pancreatic cancer research, especially for modeling metastasis, chemoresistance, and epithelial-to-mesenchymal transition (EMT) and is often compared with other PDAC models such as CAPAN-2 in studies of tumor heterogeneity and drug response.
| Product Code | Suit-2; SUIT 2; SUIT2; Suit2; SUIzo Tumor-2 |
| Species | Human |
| Cat.No | ABC-TC1175 |
| Product Category | Tumor Cell Lines |
| Size/Quantity | 1 vial |
| Cell Type | Epithelial-like |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Human Pancreas Cancer Cell Lines |
SUIT-2 cells are widely used for modeling pancreatic cancer metastasis, especially to the liver, and for studying molecular mechanisms behind tumor invasiveness and drug resistance. They support in vivo metastasis studies, gene knockdown/overexpression, EMT characterization, and drug screening for agents targeting KRAS-mutant PDAC. Their capacity to form subclones with distinct metastatic profiles allows for precise investigation into organ-specific colonization.
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $200 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
Chen WC, To MD, Westcott PMK, et al. Targeting KRAS4A splicing through the RBM39/DCAF15 pathway inhibits cancer stem cells. Nat Commun. 2021;12(1):4288. Published 2021 Jul 13. doi:10.1038/s41467-021-24498-7
